Pertuzumab (Perjeta®, Genentech) is a recombinant humanized IgG1k monoclonal antibody binding the extracellular dimerization subdomain II of the human epidermal growth factor 2 (HER2). In June 2012, FDA granted full approval for the treatment of HER2-positive metastatic breast cancer (mBC), in association with trastuzumab and docetaxel, in patients not previously treated with anti-HER2 therapy or with chemotherapy. The CHMP Committee from EMEA issued a positive opinion in December 2012 for the use of pertuzumab in the same combination therapy in HER2-positive mBC or in locally recurrent unresectable breast cancer (BC), with the same therapeutic limitations, and final approval was issued in March 2013.
KeywordsFebrile Neutropenia Inflammatory Breast Cancer Mucosal Inflammation Tyrosine Kinase Pathway Triplet Combination
- 1.Pertuzumab (Perjeta®) BLA125409 Medical Review FDA, June 2012Google Scholar
- 2.Pertuzumab (Perjeta®) Prescribing Information Genentech, June 2012Google Scholar
- 3.Pertuzumab (Perjeta®) WC500141004 Assessment Report, EMEA Dec 2012Google Scholar
- 9.Gianni L, Pienkowski T, Im Y-H et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32PubMedCrossRefGoogle Scholar
- 12.Agus DB, Sweeney CJ, Morris MJ et al (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25:675–681PubMedCrossRefGoogle Scholar
- 15.Kaye SB, Poole CJ, Dańska-Bidzińska A et al (2013) A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 24:145–152PubMedCrossRefGoogle Scholar